You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Identifying the Patient With Atrial Fibrillation in Primary Care

  • Authors: Keith A. A. Fox, MBChB, FRCP, FMedSci; Christian T. Ruff, MD, MPH; Charles P. Vega, MD
  • CME / ABIM MOC Released: 12/8/2017
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 12/8/2018, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for primary care physicians, cardiologists, and other healthcare professionals who treat patients with or at risk for atrial fibrillation (AF).

The goal of this activity is to provide an update on strategies to improve detection of AF in primary care practice patients.

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Patient assessment criteria to detect AF in the primary care setting


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Keith A. A. Fox, MBChB, FRCP, FMedSci

    Professor of Cardiology, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom

    Disclosures

    Disclosure: Keith A. A. Fox, MBChB, FRCP, FMedSci, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bayer AG; GlaxoSmithKline; Janssen Pharmaceuticals
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer AG; Janssen Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi

    Dr Fox does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Fox does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Christian T. Ruff, MD, MPH

    Assistant Professor of Medicine, TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachus

    Disclosures

    Disclosure: Christian T. Ruff, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Portola Pharmaceuticals, Inc.
    Received grants for clinical research from: Daiichi Sankyo, Inc.

    Dr Ruff does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ruff does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Charles P. Vega, MD

    Clinical Professor, Family Medicine, School of Medicine, University of California, Irvine

    Disclosures

    Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Served as a speaker or a member of a speakers bureau for: Shire

    Dr Vega does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Vega does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

  • Keith A. A. Fox, MBChB, FRCP, FMedSci

    Disclosures

    As listed above.

  • Jan Beyer-Westendorf, MD

    Assistant Professor, University Hospital Carl Gustav Carus der Technische Universität Dresden, Dresden, Germany

    Disclosures

    Disclosure: Jan Beyer-Westendorf, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; LEO Pharma; Pfizer Inc
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; LEO Pharma; Pfizer Inc
    Received grants for clinical research from: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Pfizer Inc

  • Craig I. Coleman, PharmD

    Professor of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, Connecticut

    Disclosures

    Disclosure: Craig I. Coleman, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals
    Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals

  • Graeme J. Hankey, MBBS, MD, FRACP, FRCP, FRCPE

    Winthrop Professor of Neurology, School of Medicine and Pharmacology, The University of Western Australia; Consultant Neurologist, Department of Neurology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia

    Disclosures

    Disclosure: Graeme J. Hankey, MBBS, MD, FRACP, FRCP, FRCPE, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals

  • Gilles Montalescot, MD, PhD

    Professor of Cardiology, Institut de Cardiologie, Hôpital la Pitié-Salpêtrière, Paris, France

    Disclosures

    Disclosure: Gilles Montalescot, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Accumetrics, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare Pharmaceuticals; BIOTRONIK; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Iroko Pharmaceuticals, LLC; Lilly; Medtronic, Inc.; Menarini; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche; Sanofi; The Medicines Company
    Received grants for clinical research from: Abbott Laboratories; Accumetrics, Inc.; AstraZeneca Pharmaceuticals LP; BIOTRONIK; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Lilly; Medtronic, Inc.; Menarini; Nanosphere, Inc.; Pfizer Inc; Roche; The Medicines Company

  • Christian T. Ruff, MD, MPH

    Disclosures

    As listed above.

  • Peter Verhamme, MD, PhD

    Professor, University of Leuven, Leuven, Belgium

    Disclosures

    Disclosure: Peter Verhamme, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; LEO Pharma; Pfizer Inc; Portola Pharmaceuticals; Sanofi
    Received grants for clinical research from: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Sanofi

Editor

  • Caroline M. Padbury, BPharm

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Caroline M. Padbury, BPharm, has disclosed no relevant financial relationships.

CME Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories; HeartWare International, Inc.; Medtronic, Inc.; Thoratec Corporation


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Identifying the Patient With Atrial Fibrillation in Primary Care

Authors: Keith A. A. Fox, MBChB, FRCP, FMedSci; Christian T. Ruff, MD, MPH; Charles P. Vega, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/8/2017

Valid for credit through: 12/8/2018, 11:59 PM EST

processing....

Transkription in Deutsch

Download the pdf.

« Return to: Identifying the Patient With Atrial Fibrillation in Primary Care
  • Print